Contact your trial team or GP promptly if you experience: Persistent or severe nausea, vomiting, or diarrhoea that prevents adequate fluid or food intake Signs of dehydration, such as dizziness, dark urine, or reduced urination Severe or persistent abdominal pain, which may rarely indicate pancreatitis a known risk with GLP-1 receptor agonist therapies or gallbladder problems [18] [21] Rapid or irregular heartbeat (palpitations) Significant injection site reactions, including signs of infection (redness, warmth, swelling, or discharge) Symptoms of low blood sugar (hypoglycaemia) if you are also taking insulin or a sulfonylurea, such as shakiness, sweating, or confusion If you are unsure whether your symptoms require urgent attention, contact NHS 111 (by phone or online at 111.nhs.uk) for advice
Pederson, R
Reduced benefits: Using doses that are too low may limit benefit, while stopping or adjusting treatment without follow-up can interfere with long-term metabolic or health goals
Other studies have suggested that there is no significant difference in the risk of acute pancreatitis or pancreatic cancer between the two groups when GLP-1RA is used (84, 85)
Diabetes (1999) 48:SA2022
People with gastroparesis or slow gastric motility GLP-1 agonists further slow already-compromised gastric emptying
